. Author manuscript; available in PMC: 2014 Mar 1.

Published in final edited form as: Int J Cancer. 2012 Sep 1;132(5):1191–1200. doi: 10.1002/ijc.27753

Table 3. Associations between the IGF-1/ IGFBP-3 ratio and breast-cancer and all-cause mortality.

	Events /N total	Unadjusted			Model 1^a

		HR	95% CI	P	HR	95% CI	P
Breast cancer Mortality

IGF-1/IGFBP-3 Quintiles (×10⁻³)
9.35-20.74	11/120	1.00	Ref.	Ref.	1.00	Ref.	Ref.
20.76-27.29	8/120	0.71	0.29-1.78	0.47	0.86	0.33-2.23	0.76
27.30-33.57	7/120	0.61	0.23-1.58	0.31	0.98	0.34-2.84	0.97
33.60-41.45	5/120	0.43	0.15-1.24	0.12	0.83	0.25-2.80	0.77
41.47-91.07	11/120	0.94	0.39-2.25	0.89	1.74	0.56-5.40	0.34

All-cause Mortality

IGF-1/IGFBP-3 Quintiles (×10⁻³)
9.35-20.74	19/120	1.00	Ref.	Ref.	1.00	Ref.	Ref.
20.76-27.29	20/120	1.39	0.72-2.68	0.32	1.63	0.83-3.19	0.15
27.30-33.57	14/120	0.93	0.46-1.90	0.84	1.34	0.63-2.88	0.44
33.60-41.45	14/120	0.88	0.44-1.81	0.74	1.33	0.60-2.99	0.47
41.47-91.07	20/120	1.64	0.83-3.21	0.15	2.83	1.26-6.36	0.01

Adjusted for BMI (categorical <18.5; ≥ 18.5 and < 25; ≥ 25 and < 40; > 40 kg/m²); Ethnicity/ Study Site; tamoxifen use at time of blood draw (Yes/No); Treatment received at diagnosis (Surgery/Radiotherapy+Surgery/Chemotherapy)